Sciton announces the publication of a new multi-center clinical study, “Hybrid Fractional Laser: A Multi-Center Trial on the Safety and Efficacy for Photorejuvenation,” in the November issue of the Journal of Drugs in Dermatology (JDD) in a special issue for lasers, light sources, and devices.
“This study further proves that the HALO Hybrid Fractional Laser offers a safe and effective treatment for a multitude of skin conditions on the face and neck while giving patients the results they desire with limited downtime,” says Jill Waibel, MD, Miami Dermatology and Laser Institute, in a media release from Sciton.
“We are proud to offer our customers, patients, and business partners substantial clinical evidence that the HALO Hybrid Fractional Laser delivers high patient satisfaction, results they demand, and with the minimal downtime they expect,” states Lacee J. Naik, Director of Global Marketing
The HALO Hybrid Fractional Laser is designed to apply tunable non-ablative (1470nm) and ablative (2940nm) wavelengths to the same microscopic treatment zone to maximize results and reduce downtime and produce targeted, reproducible, effective results that improve the appearance of numerous skin conditions.
Intelligent energy delivery, combined with Dynamic Thermal Optimization, ensures precise, even, safe treatments. As part of the multifaceted, expandable JOULE platform, HALO provides the practitioner with a dynamic and essential component of their aesthetic toolbox, the release continues.
[Source(s): Sciton Inc, PR Newswire]
